Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

Influenza, Human Clinical Trial

Official title:

Phase III Study to Evaluate Immunogenicity and Safety of 'Il-Yang Quadrivalent Seasonal Influenza Vaccine' in Healthy Korean Children and Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03445468
• Other study ID #: IF4CH03
• Status: Completed
• Phase: Phase 3
• Start date: September 20, 2017
• Est. completion date: August 30, 2018

Study information

• Verified date: August 2018
• Source: Il-Yang Pharm. Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.

Description:

The study is an open-label(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active comparator(Part 2) Phase III study.

Before initiation of any protocol-specific activities, written informed consent is obtained from each patient and their legally acceptable representatives. Subjects who meet all of the eligibility criteria after screening assessments as specified in the protocol, are randomized into the test group or the comparator group in a ratio of 4 :1 and receive a single dose or two doses of the study vaccine. The investigator perform the efficacy (immunogenicity) and safety assessments throughout the study. Efficacy data are collected at Visit 1 (prior to vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for safety assessment, subjects and their legally acceptable representatives are instructed to record any treatment-emergent adverse event in Patient Diary cards.

For all randomized subjects, blood sample is obtained prior to vaccination, and the study vaccine 0.5mL is administered. For children aged from 3 years to <9 years of age who have not previously received influenza vaccine, another dose of the study vaccine is administered 4 to 5 weeks after the first dose. Blood samples are collected 4 to 5 weeks after the last dose of the study drug for the assessment of antibody titer. All subjects are followed for 6 months after the last dose of the study drug for the safety assessments, and Month 6 follow-up visit is the end-of-study visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 379
• Est. completion date: August 30, 2018
• Est. primary completion date: December 29, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 3 Years to 18 Years

Eligibility

Inclusion Criteria:

• Healthy men or women aged from 3 years to < 19 years

• Subjects were born after full term pregnancy (37 weeks)

• Woman of childbearing potential must have a negative result from Urine Human Chorionic Gonadotropin(HCG) test at the screening visit.

• Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 7 years of age)

Exclusion Criteria:

• Subject with a known serious allergy reaction after influenza vaccination or to any component vaccine including eggs

• Subject who had received an influenza vaccine within the last 6 months

• Subject who has, or has a family history of, an immune system disorder including immune deficiency disease

• Subject with a history of Guillain-Barre syndrome

• Subject with Down's syndrome or cytogenetic disorders.

• Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial

• Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection

• Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine

• Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.

• Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine

• Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.

• Subject who had participated in another experimental study within 28 days prior to administration of the study vaccine

• Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• IL-YANG Quadrivalent Influenza Vaccine
A single 0.5mL dose administrated as an intramuscular injection.
• IL-YANG Flu Vaccine Pre-filled Syringe
A single 0.5mL dose administrated as an intramuscular injection.

Locations

Country	Name	City	State
Korea, Republic of	The catholic university of Korea, Seoul ST. Marry's Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Il-Yang Pharm. Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroconversion rate against Hemagglutination Inhibition(HI) antibody	Seroconversion rate(a lower bound of 95 CI) = 40%	Up to Day28(+7) after the last vaccination
Primary	Seroprotection rate against Hemagglutination	Seroprotection rate(a lower bound of 95 CI) = 70%	Up to Day28(+7) after the last vaccination
Secondary	Geometric Mean Titer(GMT) and Geometric Mean Ratio(GMR)	GMT and GMR of HI Antibody Titer Before Vaccination and After Vaccination	Up to Day28(+7) after the last vaccination